BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:America/Phoenix X-WR-TIMEZONE:America/Phoenix BEGIN:VEVENT UID:1775@azbio.org DTSTART;TZID=America/Phoenix:20221213T090000 DTEND;TZID=America/Phoenix:20221213T100000 DTSTAMP:20221209T161131Z URL:https://www.azbio.org/events/htg-therapeutics-key-opinion-leader-kol-w ebinar-the-role-of-rna-profiling-in-drug-discovery-and-analysis SUMMARY:HTG Therapeutics key opinion leader (KOL) webinar: “The Role of R NA Profiling in Drug Discovery and Analysis” - - 13 Dec 22 09:00 DESCRIPTION:\n\nTUCSON\, Ariz.\, Dec. 09\, 2022 (GLOBE NEWSWIRE) -- HTG Mol ecular Diagnostics\, Inc. (Nasdaq: HTGM) (HTG)\, a life science company ad vancing precision medicine through its innovative transcriptome-wide profi ling and advanced medicinal chemistry technology\, today announced it will host its next HTG Therapeutics key opinion leader (KOL) webinar: “The R ole of RNA Profiling in Drug Discovery and Analysis”\, on Tuesday\, Dece mber 13\, 2022 at 11:00 am Eastern Standard Time.\n\nThis latest webinar f eatures a presentation from KOL\, Dr. Robert Spitale\, PhD\, from the Univ ersity of California - Irvine\, discussing the use of RNA profiling in the drug discovery process to better uncover mechanism of action and refine t he drug screening processes.\n\nAdditionally\, the HTG Therapeutics team w ill present results from the application of its transcriptome-informed dru g discovery process. Specifically\, differential regulation of the ferropt osis pathway by structurally similar compounds that target mTOR will be of fered as an example of how RNA profiling can aid in understanding post-tar get engagement consequences and expand our understanding of the biological implications of compound treatment.  \n\nHTG Therapeutics\, the company ’s drug discovery business unit\, is actively using its transcriptome-in formed approach to drug discovery to design and further refine small-molec ule chemical libraries. The goal of this approach is to enable the selecti on and characterization of de-risked candidate molecules across selected t herapeutic targets of interest leading to potential business development a nd licensing opportunities in various therapeutic areas. A video providing an overview of HTG’s Therapeutics business and a link to the replay of initial presentation in this KOL series are available on the Company’s w ebsite HERE.\n\nA live question and answer session will follow the present ations. Please register for the event HERE.\n\nAbout KOL Dr. Spitale:\n\nD r. Spitale currently serves as the Associate Director and Associate Dean o f Research in the School of Pharmacy &\; Pharmaceutical Sciences at Uni versity of California\, Irvine (UCI). After joining UCI Pharmaceutical Sci ences Department as an Assistant Professor in 2014\, he was promoted to As sociate Professor in 2018\, and rose to the ranks of Professor in 2020. In this time\, Dr. Spitale’s research has focused on developing novel chem ical and bioinformatic approaches toward understanding the role of RNA str ucture and function in normal biology as well as disease. Beyond his resea rch accomplishments\, he has been an active presence in the UCI community as the Director of the RNA Club and its annual symposium\, a co-founder of the Chemical and Systems Biology Club and the faculty advisor for the Pha rm Sci undergraduate student council. He is also a vital part of the devel opment of the planned School of Pharmacy and Pharmaceutical Sciences\, hav ing served on the Pharmacy Planning group responsible for creating proposa ls to the UCI Senate\, UC System\, and the Accreditation Council for Pharm acy Education (ACPE). Dr. Spitale received his Ph.D. degree in Chemistry a t the University of Rochester in 2009\, as an Elon Huntington Hooker Fello w with Professor Joseph Wedekind. He then transitioned to postdoctoral stu dies at Stanford University and was awarded the A.P. Giannini Fellowship t o support his research with Professor Howard Chang.\n\nAbout HTG: \n\nHTG is accelerating precision medicine from diagnosis to treatment by harnessi ng the power of transcriptome-wide profiling to drive translational resear ch\, novel therapeutics and clinical diagnostics across a variety of disea se areas.\n\nBuilding on more than a decade of pioneering innovation and p artnerships with biopharma leaders and major academic institutes\, HTG’s proprietary RNA platform technologies are designed to make the developmen t of life science tools and diagnostics more effective and efficient and t o unlock a differentiated and disruptive approach to transformative drug d iscovery. For more information visit www.htgmolecular.com.\n\nForward-Look ing Statements:\n\nStatements contained in this press release regarding ma tters that are not historical facts are “forward-looking statements” w ithin the meaning of the Private Securities Litigation Reform Act of 1995\ , including statements regarding the capabilities and benefits of using RN A profiling in the drug discovery process\, results that may be implied fr om prior results\, the goals of HTG transcriptome-informed drug discovery approach and the ability to achieve those goals\, and the design and poten tial benefits of HTG’s RNA platform technologies. Words such as “belie ves\,” “plans\,” “can\,” “expects\,” “intends\,” “will \,” “goal\,” “potential” and similar expressions are intended to identify forward-looking statements\, although not all forward-looking st atements necessarily contain these identifying words. These forward-lookin g statements are based upon management’s current expectations\, are subj ect to known and unknown risks\, and involve assumptions that may never ma terialize or may prove to be incorrect. Actual results and the timing of e vents could differ materially from those anticipated in such forward-looki ng statements as a result of various risks and uncertainties\, including\, without limitation\, risks associated with drug discovery and development \; past results may not be indicative of future results\; the risk that ou r RNA platform and medicinal chemistry technologies may not provide the be nefits that we expect\; risks associated with our ability to develop and c ommercialize our products\; the risk that our products and services may no t be adopted by biopharmaceutical companies or other customers as anticipa ted\, or at all\; our ability to manufacture our products to meet demand\; competition in our industry\; additional capital and credit availability\ ; our ability to attract and retain qualified personnel\; risks associated with the impact of the COVID-19 pandemic on us and our customers\; and pr oduct liability claims. These and other factors are described in greater d etail in our filings with the Securities and Exchange Commission (SEC)\, including under the “Risk Factors” heading of our Quarterly Report on Form 10-Q for the quarter ended September 30\, 2022\, as filed with the  SEC on November 10\, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made\, and we undertake no obligation to update such statements to reflect events th at occur or circumstances that exist after the date on which they were mad e\n\nInvestor Contact:                           \n\nAshley Robinson                      \nLifeSci Advisors                                \nPhone: (617) 4 30-7577                      \nEmail: arr@lifesciadv isors.com END:VEVENT BEGIN:VTIMEZONE TZID:America/Phoenix X-LIC-LOCATION:America/Phoenix BEGIN:STANDARD DTSTART:20211213T090000 TZOFFSETFROM:-0700 TZOFFSETTO:-0700 TZNAME:MST END:STANDARD END:VTIMEZONE END:VCALENDAR